Congo Launches Mpox Vaccination Campaign to Address Outbreak

By Crystal Lubbe

October 23, 2024

The article from the World Health Organization (WHO) Regional Office for Africa, titled “The Democratic Republic of the Congo kicks off mpox vaccination,” provides crucial information regarding the launch of the mpox vaccination campaign in the Democratic Republic of the Congo. This initiative marks a significant effort to combat the ongoing mpox outbreak and is essential for safeguarding public health.

Launch of Vaccination Campaign

The Democratic Republic of the Congo (DRC) launched its mpox vaccination campaign on October 5, 2024, in the eastern North Kivu province. This initiative is part of the ongoing efforts to control the mpox outbreak and save lives.

Target Groups

The vaccination will prioritise several groups, including health workers, frontline responders, and other at-risk groups. The campaign will subsequently expand to 11 of the most affected health zones in Equateur, North Kivu, Sankuru, South Kivu, Sud-Ubangi, and Tshopo provinces.

Vaccine Supply

The country has received 265,000 doses of the MVA-BN vaccine, donated by the European Commission’s Health Emergency Preparedness and Response Authority, Gavi, the Vaccine Alliance, and the United States Government.

Comprehensive Response

WHO recommends that mpox vaccination be part of a comprehensive response, which includes enhanced surveillance, community engagement, contact tracing, public health and social measures, and appropriate case management. As a result, WHO and partners are working closely with national authorities to scale up and reinforce these control measures.

Expert Support

More than 300 WHO experts, previously involved in polio eradication, have now joined the mpox response. With extensive field experience, they contribute to community-based and health-facility surveillance, case investigations, contact tracing, and risk communication.

Preparation and Infrastructure

WHO has supported national health authorities in various areas, including training health workers and enhancing vaccine delivery systems and infrastructure, including vaccine storage and transportation. Furthermore, community engagement and ensuring supervision for the vaccination process are also priorities. As a result, efforts are underway to address vaccine misinformation and engage with community and religious leaders.

Mpox Situation in DRC

In 2024, the DRC has reported over 30,000 laboratory-confirmed mpox cases and 990 deaths. This accounts for 90% of the cases reported in the African region this year.

Vaccine Availability and Distribution

Mpox vaccines are currently in short supply, especially in Africa. The MVA-BN vaccine received WHO’s prequalification in September 2024, which facilitates timely access. Moreover, WHO is collaborating with partners to establish a distribution mechanism for donated doses and direct procurements from the vaccine manufacturer.

In conclusion, the vaccination campaign is a critical step in addressing the mpox outbreak in the Democratic Republic of Congo. Furthermore, this effort is supported by a comprehensive strategy that integrates multiple public health measures and emphasizes international collaboration.

Reference url

Recent Posts

pharmaceutical industry Europe
    

Pharmaceutical Industry Europe: Key Insights and Future Challenges for 2025

💡 How is the pharmaceutical industry in Europe poised to navigate the challenges of 2025?

As the industry faces fierce competition, regulatory hurdles, and evolving market dynamics, this article provides key insights into R&D investments, employment trends, and the urgent need for policy reforms. Discover how Europe can leverage its strengths to maintain its leadership in global life sciences.

Jump into these pivotal developments and strategies by reading the full article!

#SyenzaNews #pharmaceuticals #healthcarepolicy

prior authorization reforms
     

Streamlining Prior Authorization Reforms: Impacts and Insights for HEOR

🚀 Are prior authorizations stalling care delivery in the U.S. healthcare system?

The HHS has launched an ambitious collaboration with major insurers to reform prior authorization processes across Medicare Advantage, Medicaid, and commercial plans. With a goal to standardize submissions by 2027 and significantly reduce requirements by 2026, this initiative promises to accelerate care decisions and enhance transparency.

Dive into the details of these pivotal reforms and discover their potential to streamline healthcare and improve patient outcomes.

#SyenzaNews #HealthcareInnovation #healthcare #healthcarepolicy

private health funding
    

Private Health Funding Under South Africa’s National Health Insurance Act

🚀 Update on NHI in South Africa.

In their insightful article, Solanki et al. discuss the complexities of private health funding amidst the nation’s National Health Insurance Act. They discuss two key scenarios: a passive approach that risks the sustainability of the private sector and an active reform strategy that could ensure a smoother transition to universal coverage.

Curious about how these strategies could reshape healthcare access and costs in South Africa? Don’t miss out on this critical analysis!

#SyenzaNews #HealthEconomics #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.